Clinical studies recruiting near Galesburg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Illinois CancerCare-Galesburg · NRG Oncology · NCT05624996 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT07321652 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT07091617 A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Illinois CancerCare Galesburg · Pfizer · NCT07144280 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Illinois CancerCare-Galesburg · NRG Oncology · NCT05946213 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · Illinois CancerCare-Galesburg · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Illinois CancerCare-Galesburg · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT06632327 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT06931340 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT04269902 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · Illinois CancerCare-Galesburg · NRG Oncology · NCT06748222 Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA
NA · Illinois CancerCare-Galesburg · Wake Forest University Health Sciences · NCT06904391 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT04242095 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Illinois CancerCare-Galesburg · Eastern Cooperative Oncology Group · NCT05108298 Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT07061964 Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Illinois CancerCare - Galesburg · Pfizer · NCT07222800 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Illinois CancerCare-Galesburg · ECOG-ACRIN Cancer Research Group · NCT04566328 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Illinois CancerCare-Galesburg · NRG Oncology · NCT04852887 Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Phase N/A · Illinois CancerCare-Galesburg · Wake Forest University Health Sciences · NCT03998202 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT05677490 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT06058377 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · Illinois CancerCare-Galesburg · SWOG Cancer Research Network · NCT04511013 Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · Illinois CancerCare-Galesburg · Alliance for Clinical Trials in Oncology · NCT07215910 An Internet-based Program to Help Cancer Survivors Manage Pain
NA · Illinois CancerCare-Galesburg · Wake Forest University Health Sciences · NCT04462302 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Illinois CancerCare-Galesburg · ECOG-ACRIN Cancer Research Group · NCT04239573 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT05987241 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Illinois CancerCare-Galesburg · National Cancer Institute (NCI) · NCT05564377 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Illinois CancerCare-Galesburg · SWOG Cancer Research Network · NCT04205968

Look up another city

Look up another condition